McDonald's Plans Smaller, Higher-Protein Menu to Stay Relevant in the Ozempic Era

McDonald's intends to remain appealing as appetite-suppressing drugs such as Ozempic reshape consumer eating habits, according to a report in the Süddeutsche Zeitung. The fast-food chain's response is a menu strategy built around smaller portions and dishes containing more protein. The Süddeutsche Zeitung frames the shift as a matter that should worry more than just the company's shareholders, pointing to wider consequences for the fast-food industry and its investors. The report ties the planned changes directly to the so-called Ozempic era, in which demand for weight-loss medications is altering what customers order. No launch dates, specific menu items, prices, or named McDonald's executives are given in the source material. The article appears in the newspaper's culture section under the title "Fast Food: Big Protein."